Indications of stereotactic irradiation for brain lesions

Naoyuki Shigematsu, E. Kunieda, O. Kawaguchi, A. Takeda, N. Ihara, S. Yamashita, A. Kubo, H. Ito

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Stereotactic radiosurgery (SRS: single-fraction stereotactic irradiation) was originally developed to treat benign lesions in the brain, and has been adopted for the treatment of small primary or metastatic brain tumours. It has recently been recommended that stereotactic radiotherapy (SRT: fractionated stereotactic irradiation) be applied to the treatment of brain tumours; however, it requires much more time and work than SRS, and sufficient radiobiological evaluations of these techniques have never been carried out. Biologically effective doses were calculated to determine the indications for SRS and SRT, and to decide on an effective SRT schedule, incorporating the factors of 'repair' and 'cell proliferation'. The results suggest that SRS would be recommended for arteriovenous malformations and benign tumours that have distinct margins separating them from surrounding normal tissue and SRT would be recommended for benign or malignant brain tumours without clearly defined boundaries. The recommended SRT schedules would be 7 Gy x 7 fractions every other day for malignant tumours and 3.5 Gy x 12 fractions every other day for benign tumours. However, clinically, these schedules should be modified according to many other factors in individual cases.

Original languageEnglish
Pages (from-to)597-603
Number of pages7
JournalActa Oncologica
Volume39
Issue number5
Publication statusPublished - 2000

Fingerprint

Brain Neoplasms
Appointments and Schedules
Brain
Neoplasms
Radiosurgery
Arteriovenous Malformations
Radiotherapy
Cell Proliferation
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Shigematsu, N., Kunieda, E., Kawaguchi, O., Takeda, A., Ihara, N., Yamashita, S., ... Ito, H. (2000). Indications of stereotactic irradiation for brain lesions. Acta Oncologica, 39(5), 597-603.

Indications of stereotactic irradiation for brain lesions. / Shigematsu, Naoyuki; Kunieda, E.; Kawaguchi, O.; Takeda, A.; Ihara, N.; Yamashita, S.; Kubo, A.; Ito, H.

In: Acta Oncologica, Vol. 39, No. 5, 2000, p. 597-603.

Research output: Contribution to journalArticle

Shigematsu, N, Kunieda, E, Kawaguchi, O, Takeda, A, Ihara, N, Yamashita, S, Kubo, A & Ito, H 2000, 'Indications of stereotactic irradiation for brain lesions', Acta Oncologica, vol. 39, no. 5, pp. 597-603.
Shigematsu N, Kunieda E, Kawaguchi O, Takeda A, Ihara N, Yamashita S et al. Indications of stereotactic irradiation for brain lesions. Acta Oncologica. 2000;39(5):597-603.
Shigematsu, Naoyuki ; Kunieda, E. ; Kawaguchi, O. ; Takeda, A. ; Ihara, N. ; Yamashita, S. ; Kubo, A. ; Ito, H. / Indications of stereotactic irradiation for brain lesions. In: Acta Oncologica. 2000 ; Vol. 39, No. 5. pp. 597-603.
@article{e2f7d67681bc4197913c285acc9111f5,
title = "Indications of stereotactic irradiation for brain lesions",
abstract = "Stereotactic radiosurgery (SRS: single-fraction stereotactic irradiation) was originally developed to treat benign lesions in the brain, and has been adopted for the treatment of small primary or metastatic brain tumours. It has recently been recommended that stereotactic radiotherapy (SRT: fractionated stereotactic irradiation) be applied to the treatment of brain tumours; however, it requires much more time and work than SRS, and sufficient radiobiological evaluations of these techniques have never been carried out. Biologically effective doses were calculated to determine the indications for SRS and SRT, and to decide on an effective SRT schedule, incorporating the factors of 'repair' and 'cell proliferation'. The results suggest that SRS would be recommended for arteriovenous malformations and benign tumours that have distinct margins separating them from surrounding normal tissue and SRT would be recommended for benign or malignant brain tumours without clearly defined boundaries. The recommended SRT schedules would be 7 Gy x 7 fractions every other day for malignant tumours and 3.5 Gy x 12 fractions every other day for benign tumours. However, clinically, these schedules should be modified according to many other factors in individual cases.",
author = "Naoyuki Shigematsu and E. Kunieda and O. Kawaguchi and A. Takeda and N. Ihara and S. Yamashita and A. Kubo and H. Ito",
year = "2000",
language = "English",
volume = "39",
pages = "597--603",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Indications of stereotactic irradiation for brain lesions

AU - Shigematsu, Naoyuki

AU - Kunieda, E.

AU - Kawaguchi, O.

AU - Takeda, A.

AU - Ihara, N.

AU - Yamashita, S.

AU - Kubo, A.

AU - Ito, H.

PY - 2000

Y1 - 2000

N2 - Stereotactic radiosurgery (SRS: single-fraction stereotactic irradiation) was originally developed to treat benign lesions in the brain, and has been adopted for the treatment of small primary or metastatic brain tumours. It has recently been recommended that stereotactic radiotherapy (SRT: fractionated stereotactic irradiation) be applied to the treatment of brain tumours; however, it requires much more time and work than SRS, and sufficient radiobiological evaluations of these techniques have never been carried out. Biologically effective doses were calculated to determine the indications for SRS and SRT, and to decide on an effective SRT schedule, incorporating the factors of 'repair' and 'cell proliferation'. The results suggest that SRS would be recommended for arteriovenous malformations and benign tumours that have distinct margins separating them from surrounding normal tissue and SRT would be recommended for benign or malignant brain tumours without clearly defined boundaries. The recommended SRT schedules would be 7 Gy x 7 fractions every other day for malignant tumours and 3.5 Gy x 12 fractions every other day for benign tumours. However, clinically, these schedules should be modified according to many other factors in individual cases.

AB - Stereotactic radiosurgery (SRS: single-fraction stereotactic irradiation) was originally developed to treat benign lesions in the brain, and has been adopted for the treatment of small primary or metastatic brain tumours. It has recently been recommended that stereotactic radiotherapy (SRT: fractionated stereotactic irradiation) be applied to the treatment of brain tumours; however, it requires much more time and work than SRS, and sufficient radiobiological evaluations of these techniques have never been carried out. Biologically effective doses were calculated to determine the indications for SRS and SRT, and to decide on an effective SRT schedule, incorporating the factors of 'repair' and 'cell proliferation'. The results suggest that SRS would be recommended for arteriovenous malformations and benign tumours that have distinct margins separating them from surrounding normal tissue and SRT would be recommended for benign or malignant brain tumours without clearly defined boundaries. The recommended SRT schedules would be 7 Gy x 7 fractions every other day for malignant tumours and 3.5 Gy x 12 fractions every other day for benign tumours. However, clinically, these schedules should be modified according to many other factors in individual cases.

UR - http://www.scopus.com/inward/record.url?scp=0033775250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033775250&partnerID=8YFLogxK

M3 - Article

C2 - 11093367

AN - SCOPUS:0033775250

VL - 39

SP - 597

EP - 603

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 5

ER -